BCEL

Atreca
BCEL

About: Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Employees: 90

Healthcare Pharmaceutical Preparations

Delisted

BCEL was delisted on the 19th of March, 2024.

Back to rankings

Financial journalist opinion

Why Is Atreca (BCEL) Stock Up 85% Today?

Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Securities and Exchange Commission (SEC), Baker Bros.

Why Is Atreca (BCEL) Stock Up 85% Today?

BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.'s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a collection of antibody-related assets and materials is fair to Atreca shareholders. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. On behalf of Atreca shareholders, H.

BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (Nasdaq: IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials. “We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our.

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

See News Rankings